Abbott Laboratories will pay $160 million to resolve claims that two of the company’s units submitted false claims to Medicare by providing kickbacks to diabetes patients, including “free” or “no cost” glucose monitors, the U.S. Department of Justice said.
The U.S. Food and Drug Administration cleared a new version of Abbott Laboratories’ continuous glucose monitoring device.
Abbott Laboratories Inc. reported higher-than-expected first-quarter 2019 profit and sales on surging demand for the company’s glucose monitoring device, but an unchanged forecast along with regulatory uncertainty kept investors on the edge.
For the second year, FCB Health Network brought together a stellar group of experts to showcase the latest offerings in virtual and augmented reality, social media, technology, hardware, artificial intelligence, cloud computing services, data visualization, design, and more for its Next: Innovation Week series.
The U.S. FDA approved for marketing DreaMed Diabetes’ Advisor Pro software to help manage diabetes treatment.
Johnson & Johnson’s diabetes care unit will shut down its business in the United States and Canada amid increased competition and after failing to find a buyer.
The blood glucose monitoring and data management company AgaMatrix and the digital health assistant developer LifeWallet announced a collaboration to bring AgaMatrix’s connected blood glucose monitoring solutions together with LifeWallet’s apps for health risk assessment and follow-up care, for improved outcomes in population health management.